A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation ; volume:13 ; number:1 ; year:2020 ; pages:449-455
Case reports in oncology ; 13, Heft 1 (2020), 449-455
- Creator
-
Imataki, Osamu
Ishida, Tomoya
Kubo, Hiroyuki
Uemura, Makiko
Nanya, Yasuhito
Kawakami, Kimihiro
Ogawa, Seishi
Kadowaki, Norimitsu
- DOI
-
10.1159/000506452
- URN
-
urn:nbn:de:101:1-2020051401064519912955
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Imataki, Osamu
- Ishida, Tomoya
- Kubo, Hiroyuki
- Uemura, Makiko
- Nanya, Yasuhito
- Kawakami, Kimihiro
- Ogawa, Seishi
- Kadowaki, Norimitsu
Other Objects (12)
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
Using 2 nd generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
Using 2 nd generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
Using 2 nd generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia